Document is current

Any future updates will be listed below

NMOSD-Schubrisiko unter Tocilizumab geringer als unter Azathioprin

Crossref DOI link: https://doi.org/10.1007/s15005-021-1866-z

Published Online: 2021-03-26

Published Print: 2021-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark